Table 3

Cross-tabulation of recommendations for surveillance intervals after detection of serrated lesions

Terdiman, McQuaid98US multisociety taskforce29NIH working group19ESGE99European Union/IARC100Surveillance interval, years
Hyperplastic (serrated) polyposis syndromeSerrated polyposis syndromeSerrated polyposis syndromeN/AN/A1
Serrated polyp proximal to splenic flexure, ≥10 mm in size, or with cytological dysplasia at any location*Sessile serrated adenoma (SSA)/polyp ≥10 mm, SSA/polyp with dysplasia, or traditional serrated adenoma (TSA)SSA/P or TSA ≥10 mm or 3 or more in number. Two or more SSA/P 10 mm in size† or any SSA/P with dysplasia†Serrated polyps ≥10 mm, or with cytological dysplasia at any size*3
SSA/polyp <10 mm with no dysplasia≥4 HPs any size proximal to sigmoid, or any proximal HP >5 mm in size, or 1–2 SSPs or TSAs <10 mm5
Distal serrated polyp <10 mmHP <10 mm in recto-sigmoid, or ≤3 HP≤5 mm proximal to sigmoidSerrated polyp <10 mm with no dysplasiaAll serrated lesions of any size without adenomatous dysplasia (no recommendation for surveillance)10 (routine screening)
  • *This proposed strategy considers hyperplastic polyps (HPs), SSAs/polyps, and traditional serrated adenomas as serrated polyps.

  • †1–3 years recommended depending on clinical circumstances. SPS should be considered.

  • NIH, national institutes of health (USA); SSP, sessile serrated polyp.